Opgen Inc

NASDAQ:OPGN   3:59:56 PM EDT
2.40
+0.08 (+3.45%)
Debt Financing / Related, Products, Regulatory

Opgen Says Maintained Balance Sheet With $10.4 Million Cash As Of Sept. 30

Published: 10/15/2020 11:51 GMT
OpGen Inc (OPGN) - Q3 Revenue $1.0 Million Versus $648,000.
Maintained Balance Sheet With $10.4 Million Cash As of September 30, 2020.
To Discontinue Acuitas Amr Gene Panel (urine) Clinical Trial and Discontinue Fish Product Line Globally by Mid-2021.
Opgen - to Focus on Pending Acuitas Amr Gene Panel (isolates) FDA Clearance & Expects to Invest Significantly in Bioinformatics.